Suggestions
Andrew Shaw
Founder & CEO of Attomarker | Associate Professor of Physical Chemistry
Professional Background
Professor Andrew Shaw is an accomplished Academic Entrepreneur, renowned for his innovative contributions to research and development within both academic and industrial sectors. With an impressive trajectory spanning over 15 years, he has excelled in the creation of multi-million-pound research opportunities, culminating in the founding of two highly successful spin-out companies. His entrepreneurial journey began with EvanesCo Ltd, a pioneering counter-terrorism initiative established in the early 2000s and successfully sold in 2006. Building on this foundation, Professor Shaw went on to establish Attomarker Ltd, a cutting-edge company that developed groundbreaking blood testing technology, which debuted in 2019 and made significant contributions during the COVID-19 pandemic.
At the heart of Attomarker’s innovative approach lies an extraordinary portfolio of diagnostic tests. This includes a 22-dimensional immunity profile, which is currently undergoing validation for the diagnosis of Long Covid, as well as an infection chip designed for the differential diagnosis of bacterial and viral infections—a timely response to the pressing issue of antimicrobial resistance. Other notable developments include a liver chip aimed at assessing liver health and managing conditions such as type 2 diabetes, alongside a women’s health chip that provides comprehensive profiling of the reproductive cycle. Professor Shaw’s research group at the University not only fosters the development of new ideas but also encourages entrepreneurship, allowing for the possibility of commercializing promising research and exploring concepts that may satisfy intellectual curiosity.
Education and Achievements
Professor Shaw's robust educational background has equipped him with a wealth of knowledge and expertise. He began his academic journey at the prestigious University of Cambridge, where he studied for his MA in Natural Sciences. Following this, he pursued a PhD in Gas Phase Physical Chemistry at the University of Southampton, which laid the groundwork for his research that combines chemistry with innovative technology. Further expanding his skills, he completed his Post Doctoral Scientist work at Stanford University, where he honed his expertise in physical chemistry.
Throughout his career, Professor Shaw has held various esteemed positions in academia. He served as an Associate Professor of Physical Chemistry at the University of Exeter, where his teaching and research significantly impacted the scientific community. Additionally, he has assumed leadership roles as a Chairman at Arkiris and has taken on the crucial responsibilities of Founder and Director of Research at both Attomarker Ltd and EvanesCo Ltd. His extensive experience contributing to the boards of multiple spin-out companies underscores his commitment to transforming research into practical applications.
Achievements
Beyond his entrepreneurial ventures, Professor Shaw is a respected figure in the scientific community, recognized for his contributions to physical chemistry and related fields. His induction as a Fellow of the Royal Astronomical Society acknowledges his dedication to advancing our understanding of astronomical sciences, while his status as a Fellow of the Royal Society of Chemistry highlights his commitment to the promotion of chemistry as a crucial discipline within academia and industry alike. Together, these honors reflect his influence and leadership in bridging the gap between academic theory and practical application.
In summary, Professor Andrew Shaw exemplifies the spirit of innovation and leadership in the realms of academia and entrepreneurship. His significant contributions to research and development, particularly in the field of health technologies, alongside his extensive educational background and professional experience makes him a prominent figure in the academic and technological landscapes. Prof Shaw continues to inspire future generations of scientists and entrepreneurs through his work, emphasizing the importance of collaboration between academia and industry in addressing contemporary challenges in health and technology.
